🇺🇸 FDA
Patent

US 11629146

Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity

granted A61KA61K31/4985A61K31/5025

Quick answer

US patent 11629146 (Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity) held by PRAXIS PRECISION MEDICINES, INC. expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PRAXIS PRECISION MEDICINES, INC.
Grant date
Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/4985, A61K31/5025, A61K45/06, A61P